Trial Profile
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2019
Price :
$35
*
At a glance
- Drugs Brimonidine/brinzolamide (Primary) ; Bimatoprost; Latanoprost; Travoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Alcon
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 03 Jan 2018 Planned End Date changed from 22 Feb 2018 to 1 Feb 2018.
- 03 Jan 2018 Planned primary completion date changed from 22 Feb 2018 to 1 Feb 2018.